<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34353859</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>41</StartPage><EndPage>47</EndPage><MedlinePgn>41-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-326184</ELocationID><Abstract><AbstractText Label="BACKGROUND">Malnutrition and weight loss are negative prognostic factors for survival in patients with amyotrophic lateral sclerosis (ALS). However, energy expenditure at rest (REE) is still not included in clinical practice, and no data are available concerning hypometabolic state in ALS.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate in a referral cohort of patients with ALS the prevalence of hypometabolic state as compared with normometabolic and hypermetabolic states, and to correlate it with clinical phenotype, rate of progression and survival.</AbstractText><AbstractText Label="DESIGN">We conducted a retrospective study examining REE measured by indirect calorimetry in patients with ALS referred to Milan, Limoges and Tours referral centres between January 2011 and December 2017. Hypometabolism and hypermetabolism states were defined when REE difference between measured and predictive values was &#x2264;-10% and &#x2265;10%, respectively. We evaluated the relationship between these metabolic alterations and measures of body composition, clinical characteristics and survival.</AbstractText><AbstractText Label="RESULTS">Eight hundred forty-seven patients with ALS were recruited. The median age at onset was 63.79 years (IQR 55.00-71.17). The male/female ratio was 1.26 (M/F: 472/375). Ten per cent of patients with ALS were hypometabolic whereas 40% were hypermetabolic. Hypometabolism was significantly associated with later need for gastrostomy, non-invasive ventilation and tracheostomy placement. Furthermore, hypometabolic patients with ALS significantly outlived normometabolic (HR=1.901 (95% CI 1.080 to 3.345), p=0.0259) and hypermetabolic (HR=2.138 (95% CI 1.154 to 3.958), p=0.0157) patients.</AbstractText><AbstractText Label="CONCLUSION">Hypometabolism in ALS is not uncommon and is associated with slower disease progression and better survival than normometabolic and hypermetabolic subjects. Indirect calorimetry should be performed at least at time of diagnosis because alterations in metabolism are correlated with prognosis.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cattaneo</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO)-Fondazione Serena Onlus, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jesus</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nutrition Unit, University Hospital Centre of Limoges, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR 1094, Tropical Neuroepidemiology, University of Limoges Medical Faculty, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lizio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8875-9665</Identifier><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO)-Fondazione Serena Onlus, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayemendy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5184-580X</Identifier><AffiliationInfo><Affiliation>Inserm UMR 1094, Tropical Neuroepidemiology, University of Limoges Medical Faculty, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nutrition Unit, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guanziroli</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corradi</LastName><ForeName>Ettore</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansone</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO)-Fondazione Serena Onlus, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences of Health, University of Milan, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leocani</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Hospital, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Hospital, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0513-9517</Identifier><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Hospital, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Hospital, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>ALS Center, University Hospital of Tours, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm Unit 1253, iBrain, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Inserm UMR 1094, Tropical Neuroepidemiology, University of Limoges Medical Faculty, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de reference maladies rares SLA et autres maladies du neurone moteur, Centre Hospitalier Universitaire de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO)-Fondazione Serena Onlus, Milano, Italy christian.lunetta@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="N">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002153" MajorTopicYN="N">Calorimetry, Indirect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="Y">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: AL received compensation for occasional scientific consulting from Italfarmaco. PF, NG and EC have nothing to disclose. VS participates in Advisory Boards or Teaching activities for Biogen, Roche, Avexis, PTC, Santhera, Sarepta, Dyne. LL received honoraria for consulting services from Merck, Roche, Novartis and for speaking activities from Teva; research support from Merck, Biogen, Novartis; travel support from Merck, Roche, Biogen. MF is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, MerckSerono, Novartis, Roche, Sanofi Genzyme, Takeda and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and ARiSLA (Fondazione Italiana di Ricerca per la SLA). NR, PCor and PCou have nothing to disclose. CL served on a scientific advisory board for Mitsubishi Tanabe Pharma Europe, Cytokinetics, Neuraltus and Italfarmaco and has received funds from ARISLA and Ministry of Health (CCM2011).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34353859</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-326184</ArticleId><ArticleId IdType="pii">jnnp-2021-326184</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>